Startups
Their Autonomous Diagnostic Screening (AEYE-DS) utilizes Artificial Intelligence (AI) technology to diagnose diabetic retinopathy from retinal images. It was the first to be proven accurate on both a stationary desktop camera and a portable handheld camera. However, it should be noted that AEYE is not sold in the US.
Overview
Location
United States, New York
Employees
11-50
Founded date
2018
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 10, 2025 | Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 6.0 million | Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 6.0 million Wed, Dec 10, 2025 21:00 CET Report this content OPTOMED PLC INSIDE INFORMATION 10 December 2025, at 10 p.m. EET Inside informa... |
| Aug 7, 2025 | Optomed Plc: Half-year Report, January – June 2025 | Optomed Plc: Half-year Report, January – June 2025 Thu, Aug 07, 2025 08:00 CET Report this content Optomed Plc Stock Exchange Release 7 August 2025 at 9.00, Helsinki Optomed Plc: Half-year Report, January – June 2025 April – June 2025 Reven... |
| Apr 30, 2024 | FDA clears first fully autonomous AI for portable diabetic retinopathy screening | AEYE Health's clearance enables global prevention of the leading cause of blindness in the working age population by making screening accessible anywhere NEW YORK, April 30, 2024 /PRNewswire/ -- AEYE Health, the leading company for AI retin... |
| Apr 16, 2024 | Health | As AI eye exams prove their worth, lessons for future tech emerge | Hannah Norman | (TNS) KFF Health News Christian Espinoza, director of a Southern California drug-treatment provider, recently began employing a powerful new assistant: an artificial intelligence algorithm that can perform eye exams with pic... |
| Oct 30, 2023 | Topcon Screen and AEYE Health Announce Partnership to Enhance Diabetic Retinopathy Screening | AEYE Health, the leader in artificial intelligence-based diagnostics for retinal imaging, and Topcon Screen, a leader in point-of-care diabetic eye exams, today announced a partnership to deliver point-of-care screening for diabetic retinop... |
| Nov 15, 2022 | AI For Diabetic Retinopathy Screening Gets U.S. FDA Approval | AI-based retinal imaging and diagnostics startup AEYE Health announced today it received clearance from the FDA to market its diagnostic screening system for diabetic retinopathy. |
| Oct 7, 2020 | Israeli tech startup AEYE Health partners with Finnish camera maker Optomed to develop the world’s first handheld AI camera for diagnosis of medical conditions | Today, over a billion people worldwide and over 75 million people in the US alone are considered at high risk of developing various sight-threatening and life-threatening conditions. Over 75% of them never get checked. Enter AEYE Health, a ... |
Reviews 0
FAQ about AEYE Health
When was AEYE Health founded?
AEYE Health was founded in 2018.
What has the press written about AEYE Health?
Parsers VC has collected 8 articles mentioning AEYE Health, among them “Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 6.0 million” (Dec 10, 2025) and “Optomed Plc: Half-year Report, January – June 2025” (Aug 7, 2025).
Is AEYE Health still active?
Yes, AEYE Health is active; its latest activity on Parsers VC dates from Dec 10, 2025.